Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial tested three different doses of a drug called LY3471851 — a high dose, a middle dose, and a low dose — compared to a placebo (a dummy treatment with no active ingredient) in people with lupus, a condition where the immune system attacks the body's own tissues. A total of 291 people took part across the four groups (73 in the high-dose group, 70 in the middle-dose group, 74 in the low-dose group, and 74 in the placebo group). The trial's main goal was to measure how many participants had a meaningful reduction in their lupus disease activity score — using a standard lupus scoring tool — after 24 weeks. The reported data shows that for the primary (main) outcome — the proportion of people whose lupus disease activity score dropped by at least 4 points at 24 weeks — the figures were: 20% in the high-dose group, 27% in the middle-dose group, 22% in the low-dose group, and 22% in the placebo group. The trial also measured several secondary (additional) outcomes. For a different disease activity measure called BICLA response, the reported figures were 12% (high dose), 26% (mid dose), 18% (low dose), and 18% (placebo). For another measure called SRI-4 response, the figures matched the primary outcome: 20%, 27%, 22%, and 22% respectively. For reaching a "low disease activity state" — a defined level of reduced lupus activity — the reported figures were 12% (high dose), 18% (mid dose), 11% (low dose), and 10% (placebo). The reported data also shows drug levels measured in participants' blood just before each new dose was given: the average level was 214.4 ng/mL (nanograms per millilitre, a measure of concentration) in the high-dose group, 133.3 ng/mL in the middle-dose group, and 55.9 ng/mL in the low-dose group. It is also worth noting that fewer participants in the high-dose group completed the study (44 out of 73) compared to the placebo group (65 out of 74), though the reasons for this were not detailed in the reported data. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Lupus Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with Systemic Lupus Erythematosus (SLE, also known as lupus) for at least 24 weeks before the screening visit.
- Your diagnosis meets at least 4 out of 11 specific criteria used by doctors to officially classify lupus, based on a widely recognised medical checklist (confirm with trial site).
- Certain lupus-related proteins or antibodies have been found in your blood during screening tests, such as a positive ANA test, anti-double-stranded DNA, or anti-Smith antibody (confirm with trial site).
- Your lupus disease activity score (measured by a tool called SLEDAI-2K) is 6 or higher during the screening period (confirm with trial site).
- Your lupus disease activity score remains at 4 or higher at the point when you would be officially entered into the trial (confirm with trial site).
- You currently have active joint pain/swelling (arthritis) and/or an active skin rash related to lupus.
Who may not be able to join:
- You have severe, active lupus that is seriously affecting your kidneys.
- You have active lupus that is affecting your brain or nervous system.
- You have a serious or unstable health condition affecting the heart, lungs, liver, digestive system, hormones, blood, or nervous system that the trial doctor believes could put you at risk or affect the trial results.
- You currently have, or have recently had, a serious infection caused by a virus, bacteria, fungus, or parasite.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Study Director, Nektar Therapeutics
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
1 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Percentage of Participants Who Achieved a ≥4 Point Reduction in Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) 2000 (2K) Score at Week 24
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.